Bronchodilator reversibility testing in morbidly obese non-smokers: a comparative study– few concerns
Document Type
Article
Publication Title
BMC Pulmonary Medicine
Abstract
This is a letter in response to an article by Ahmed et al., which concluded that in comparison to salbutamol, Fluticasone/salmeterol combination increases FEV1, FEV1% of predicted, and FEV1/FVC ratio, however it did not offer novel insights, as both agents met the 12%- and 200-mL reversibility benchmarks and Concerns about incorporating a combination medication that includes an inhaled corticosteroid, inhaled corticosteroids are not typically associated with bronchodilation.
DOI
10.1186/s12890-024-02951-9
Publication Date
12-1-2024
Recommended Citation
Balan, Divya; Shetty, Manish R.; and Mohan, Manu K., "Bronchodilator reversibility testing in morbidly obese non-smokers: a comparative study– few concerns" (2024). Open Access archive. 6450.
https://impressions.manipal.edu/open-access-archive/6450